MUC1 and colon adenoma: In the phase II trial recruiting patients with recently diagnosed colonic adenomas that are not yet cancerous, a 38% absolute reduction in adenoma recurrence was observed in vaccinated patients who had an active MUC1-specific immune response at weeks 12 and 55 following initial vaccination compared to placebo (p = 0.08) [164].